Mutanocyclin, a powerful antifungal agent, inhibits the filamentation of Candida albicans (C. albicans) and decreases the mRNA expression of HWP1, ECE1, FLO8, TEC1. Furthermore, it suppresses the yeast-form in ex vivo mouse [1].

Mutanocyclin, at concentrations of 8, 16, and 32 µg/mL over 24 and 36 hours, dose-dependently inhibits the filamentation of Candida albicans (C. albicans) [1]. At a concentration of 32 µg/mL, Mutanocyclin reduces the mRNA expression of HWP1, ECE1, FLO8, and TEC1 in C. albicans cells [1]. The compound functions by modulating the PKA pathway, specifically by degrading the catalytic subunit Tpk2 and preferentially targeting its binding partner Sfl1 [1].

Mutanocyclin (32 µg/mL; 24-hour exposure) inhibits the yeast form of C. albicans in an ex vivo murine tongue infection model [1] and, at concentrations of 6.4, 12.8, and 25.6 µg/mL over 48 hours, attenuates the virulence of C. albicans in a G. mellonella infection model [1].